Curis Lifescien. — 360° view

Curis Lifescien, a company in the Pharmaceuticals industry, reported revenue of ₹34 crore and net profit of ₹4.14 crore for the September 2026 quarter.

Curis Lifescien. (NSE: CURIS-ST) closed at ₹158.00 on 20 Nov 2026. Its market capitalisation is ₹128 crore and it trades at 18.6 times earnings.

Share price
₹158.00 (20 Nov 2026)
Market cap
₹128 Cr (20 Nov 2026)
P/E
18.57 (20 Nov 2026)
Revenue
₹34 Cr (September 2026 quarter)
Net profit
₹4 Cr (September 2026 quarter)
ROCE
21.2% (FY26)
ROE
21.7% (FY26)
Book value
₹63.7 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹208.00 / ₹158.00 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: CURIS-ST

Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.